Products

Unlearn (Scout, Hindsight, SimLab)
Unlearn
Drug Discovery & Research
Unlearn leverages AI and digital twin technology to streamline clinical development, enabling faster, more robust studies, and bringing life-saving treatments to patients sooner.

See all 1 product →

About Unlearn

Unlearn is a healthcare AI company that aims to revolutionize clinical development by integrating AI and digital twins of patients. The company’s core mission is to make clinical trials smarter, faster, and more robust, ultimately accelerating the delivery of life-saving treatments to patients. Unlearn’s approach leverages data, AI, and digital twins to enhance decision-making throughout the entire clinical trial lifecycle, from initial design to post-readout analysis.

For physicians involved in clinical research, Unlearn offers tools to strengthen various stages of a study. This includes optimizing study design by pressure-testing eligibility criteria, endpoints, and sample sizes with simulated digital twins before protocol finalization. During the trial, digital twins can sharpen interim analyses and allow for re-running design scenarios as new evidence emerges. After readout, Unlearn’s technology can unlock more information from collected data, providing a clearer signal of efficacy in both randomized and single-arm studies by using digital twins as comparators. This can lead to smaller study designs, reduced control arm sizes, and faster enrollment times.

Focus Areas

AI in clinical trials digital twins synthetic control arms drug development neurodegenerative diseases oncology biostatistics machine learning

Business Intelligence

TechnologyAI-powered digital twin technology, generative machine learning models, proprietary DiGenesis™ process, PROCOVA™ (Prognostic Covariate Adjustment) statistical approach, TrialPioneer (unified workspace for trial planning)

What Physicians Need to Know

AI in Clinical Trials
Unlearn leverages AI to strengthen clinical trial decisions at every stage, from design to readout. This includes using AI for regulatory strategy expertise and generating forecasts of participant clinical outcomes.
Digital Twins
They specialize in creating AI-generated digital twins of patients. These hypothetical participants are used to model expected enrollment, pressure-test eligibility, endpoints, and sample size before protocol lock. For enrolled participants, digital twins sharpen interim analyses and can act as a comparator to unlock more information from collected data.
Synthetic Control Arms
Unlearn's digital twins can serve as a comparator, effectively reducing the need for large control arms in studies. This can lead to smaller studies, cost savings, and faster enrollment times, while still providing a clear signal of efficacy.
Drug Development Lifecycle Support
Unlearn offers solutions across the entire clinical development lifecycle: 'In Design' (before protocol finalization for sample size, eligibility, endpoints, comparators), 'In Progress' (from first patient in through readout for efficacy/futility decisions, program acceleration), and 'After Readout' (for interpretation and informing the next study design).
Key Differentiators
Unlearn's key differentiators include their focus on AI-powered precision to make decisions clearer and trials stronger, their use of digital twins to generate forecasts of individual participant outcomes, and their ability to reduce sample sizes, costs, and enrollment times while maintaining statistical power. They are also recognized as a Fierce's 2026 AI Innovation Awards winner for Clinical Trial Design.
Technology Stack
The core of their technology stack involves data, AI, and digital twins. While specific programming languages or platforms are not mentioned, the emphasis is on harnessing these elements to transform clinical development.
Physician Tip

For physicians, Unlearn's technology offers the potential for more efficient and robust clinical trials. This can translate to faster development of new treatments, especially in areas like neurodegenerative diseases and oncology, by optimizing trial design, reducing patient burden in control arms, and providing clearer insights from study data. The use of digital twins can help in making more confident decisions throughout a study, potentially accelerating the availability of life-saving therapies.

Products by Unlearn

1 product in the directory

Unlearn (Scout, Hindsight, SimLab)
Unlearn
Drug Discovery & Research
Unlearn leverages AI and digital twin technology to streamline clinical development, enabling faster, more robust studies, and bringing life-saving treatments to patients sooner.

Videos

News, demos, and interviews about Unlearn.

Loading videos...

Videos load interactively. If none appear, search YouTube for Unlearn →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Unlearn uses AI and digital twins to strengthen clinical trials, aiming to make decisions clearer and studies more robust.
Digital twins are AI-generated forecasts of a participant's clinical outcomes, used to model hypothetical participants or provide more data per enrolled participant.
Unlearn can assist at any point in a study, including during the design phase, while the study is in progress, and after readout.
It can help pressure-test eligibility, endpoints, and sample size before protocol lock, potentially leading to smaller study designs and cost savings.
Yes, digital twins can be used as a comparator to reduce the control arm size and potentially save enrollment time in clinical trials.
Unlearn's technology has been applied in neurodegenerative diseases like ALS, Alzheimer's, and Huntington's disease.
Digital twins can be used to strengthen evidence in single-arm studies, providing a clearer signal of efficacy and improving statistical power.

Investors

Who's funded Unlearn.

Related Companies

ClinicalTrials.gov is a publicly accessible website and online database of clinical research studies, managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). It serves as a central resource for patients, their families, healthcare professionals, and researchers to access comprehensive information on publicly and privately supported clinical studies across a […]

InsightRX provides AI-powered precision medicine software designed to optimize drug therapy from clinical development to the point of care. For physicians and clinical teams, InsightRX offers solutions like InsightRX Nova for Bayesian model-informed dosing, which individualizes drug regimens using validated pharmacokinetic models and real-time patient data. This helps clinicians achieve therapeutic targets more rapidly and […]

Indica Labs is a global leader in AI-powered digital pathology software and services, providing comprehensive solutions for quantitative evaluation and management of whole slide images. Their flagship platforms, HALO® and HALO AI, leverage artificial intelligence and computer vision algorithms to enable fast and precise analysis of tissue samples, which is critical for advancing research and […]

Triomics is an oncology AI company dedicated to transforming how cancer centers manage complex clinical information. The company’s platform utilizes AI agents to meticulously read and interpret comprehensive longitudinal patient records, converting unstructured clinical data—such as notes, pathology reports, imaging results, and genomic panels—into structured, verifiable outputs. This process significantly reduces the manual burden on […]

ClinTrialMatch is an AI-powered digital health platform designed to optimize patient recruitment, enrollment, and retention in clinical trials. The platform aims to bridge the gap between patients seeking treatment options and clinical trials needing participants by leveraging AI-driven insights. It is currently an early-stage platform undergoing development and pilot collaboration. For physicians, ClinTrialMatch offers a […]

Evaxion Biotech is a pioneering clinical-stage TechBio company that leverages its proprietary, clinically validated, and scalable AI platform, AI-Immunology™, to decode the human immune system. This platform is used to discover and develop novel immunotherapies for cancer, infectious diseases, and increasingly, autoimmune diseases. The company’s mission is to transform patients’ lives by providing inventive and […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.